Kymera Therapeutics Presents New Preclinical Data For KT-579, Selective, Oral IRF5 Degrader, Demonstrating Disease-Modifying Activity In Lupus Models, At EULAR And FOCIS Congresses

Loading news article.

Kymera Therapeutics Presents New Preclinical Data For KT-579, Selective, Oral IRF5 Degrader, Demonstrating Disease-Modifying Activity In Lupus Models, At EULAR And FOCIS Congresses | WAPE

Kymera Therapeutics Presents New Preclinical Data For KT-579, Selective, Oral IRF5 Degrader, Demonstrating Disease-Modifying Activity In Lupus Models, At EULAR And FOCIS Congresses

Article summary

Related companies

Comments —